---
title: "RML released its first-quarter performance, with a net profit attributable to the parent company of 68.8695 million yuan, a decrease of 30.17%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237599728.md"
description: "RML released its Q1 2025 performance, with operating revenue of 236 million yuan, a year-on-year decrease of 34.83%; net profit attributable to the parent company of 68.8695 million yuan, a year-on-year decline of 30.17%; net profit excluding non-recurring gains and losses of 63.5815 million yuan, a year-on-year decrease of 29.66%; basic earnings per share of 0.28 yuan"
datetime: "2025-04-25T15:17:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237599728.md)
  - [en](https://longbridge.com/en/news/237599728.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237599728.md)
---

# RML released its first-quarter performance, with a net profit attributable to the parent company of 68.8695 million yuan, a decrease of 30.17%

According to the Zhitong Finance APP, RML (301050.SZ) released its first-quarter report for 2025, with operating revenue of 236 million yuan, a year-on-year decrease of 34.83%. The net profit attributable to shareholders of the listed company was 68.8695 million yuan, a year-on-year decrease of 30.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 63.5815 million yuan, a year-on-year decrease of 29.66%. The basic earnings per share were 0.28 yuan

### Related Stocks

- [301050.CN](https://longbridge.com/en/quote/301050.CN.md)

## Related News & Research

- [Equatorial Maranhão board boosts Equatorial stake by R$ 7.76 million in market buys](https://longbridge.com/en/news/295444883.md)
- [Globo deploys Enensys DTV+ headend to broadcast 4K FIFA World Cup 2026 matches in Brazil](https://longbridge.com/en/news/295772191.md)
- [Infront brokers Benediktiner Weissbräu sponsorship deal with IBU Biathlon through 2029/30](https://longbridge.com/en/news/295762122.md)
- [13:44 ETCalidar Completes First-in-Human Study of Eidos Prism™ and Advances Toward 2027 Pivotal Study](https://longbridge.com/en/news/295695587.md)
- [Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study](https://longbridge.com/en/news/295661585.md)